VENUS REMEDIES
Back to Income Statement
|
VENUS REMEDIES Last 5 Year Revenue History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Net Sales | ₹648 Cr | ₹601 Cr | ₹556 Cr | ₹600 Cr | ₹548 Cr |
What is the latest Revenue of VENUS REMEDIES ?
| Year | Revenue |
|---|---|
| Mar2025 | ₹648 Cr |
| Mar2024 | ₹601 Cr |
| Mar2023 | ₹556 Cr |
| Mar2022 | ₹600 Cr |
| Mar2021 | ₹548 Cr |
How is Revenue of VENUS REMEDIES Trending?
| Years | Revenue | % Change | |
|---|---|---|---|
| Mar2025 | ₹648 Cr | 7.72 | |
| Mar2024 | ₹601 Cr | 8.27 | |
| Mar2023 | ₹556 Cr | -7.44 | |
| Mar2022 | ₹600 Cr | 9.50 | |
| Mar2021 | ₹548 Cr | - | |
Compare Revenue of peers of VENUS REMEDIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| VENUS REMEDIES | ₹2,420.6 Cr | -0.9% | 2.3% | 286.4% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹463,815.0 Cr | 0.5% | 6.2% | 17.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹192,678.0 Cr | 4.7% | 9% | 7% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹161,323.0 Cr | -3.7% | 7.2% | 49.8% | Stock Analytics | |
| CIPLA | ₹114,585.0 Cr | -0.6% | 5% | -3.2% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹101,067.0 Cr | -1.9% | -4.6% | -2.8% | Stock Analytics | |
VENUS REMEDIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| VENUS REMEDIES | -0.9% |
2.3% |
286.4% |
| SENSEX | 0.8% |
1.8% |
-6.5% |
You may also like the below Video Courses